Header Image

News

News

Filter Releases
 
News
Date Title and Summary View
Feb 15, 2017
RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its fourth quarter and full year 2016 financial results will be released on Monday, February 27, 2017.  BioCryst will host a conference call and webcast at 9:00 a.m. Eastern Time to discuss financial results and to pro...
Jan 30, 2017
RESEARCH TRIANGLE PARK, N.C., Jan. 30, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, announced today that the European Medicines Agency (EMA) has accepted the filing of its peramivir Marketing Authorization Applicati...
Jan 8, 2017
RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that Health Canada has approved RAPIVAB® (peramivir injection), an intravenous (I.V.) treatment for acute, unc...
Jan 4, 2017
RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's development programs at the 35th annual J.P. Morgan Healthcare Conference in San Francisco on Wednesd...
Nov 17, 2016
RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's clinical programs at the 28th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 30th at 8:30 a.m....
Nov 7, 2016
RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the third quarter ended September 30, 2016. "Our company's primary focus is on the execution of the APeX-1 trial of BCX7353," said Jon P. Stonehouse, President & Chief Executive Officer.  "The s...
Oct 26, 2016
RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that results from a study of galidesivir (formerly BCX4430) administered to Rhesus monkeys infected with Zika virus (ZIKV) will be presented as a late-breaker oral presentation at IDWeek 2016 taking place in New Orleans Oct...
Oct 24, 2016
RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its third quarter 2016 financial results will be released on Monday, November 7, 2016.  BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss financial results and to provide an update ...
Sep 26, 2016
Cash runway extended to early 2018; Facility to be repaid with RAPIVAB revenues  RESEARCH TRIANGLE PARK, N.C., Sept. 26, 2016 (GLOBE NEWSWIRE) --  BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the Company has closed a $23 million Senior Credit Facility with Midcap Financial. The facility was fully funded at closing and be...
Sep 7, 2016
RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced positive results from a proof-of-concept study of its broad spectrum antiviral, BCX4430, for the delayed treatment of Ebola virus infection in rhesus macaques. The goals of this 28-day study were to assess the effect ...
Aug 31, 2016
RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's clinical programs at Baird's 2016 Global Healthcare Conference in New York on Thursday, September 8th at 12:50 p.m. Eastern T...
Aug 11, 2016
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has dosed the first subject in the APeX-1 clinical trial of BCX7353 for the oral treatment of hereditary angioedema (HAE). "We are very pleased that the adaptively-designed APeX-1 trial is now under way, and lo...
Aug 4, 2016
RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the second quarter ended June 30, 2016. "We continue to make progress, and have initiated subject screening to start the APeX-1 trial evaluating our once daily oral kallikrein inhibitor BCX7353 to...
Jul 21, 2016
RESEARCH TRIANGLE PARK, N.C., July 21, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its second quarter 2016 financial results will be released on Thursday, August 4, 2016.  BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an up...
Jul 5, 2016
RESEARCH TRIANGLE PARK, N.C., July 05, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has provided additional funding for efficacy studies of BCX4430 in non-human primates to further assess effective dose regimens.  The funding represe...
Page:
...
Next Last